Description: Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France.
Home Page: www.acticor-biotech.com
Hôpital Bichat
Paris,
75018
France
Phone:
33 6 76 23 38 13
Officers
| Name | Title |
|---|---|
| Dr. Gilles Avenard M.D. | Founder, CEO & Director |
| Ms. Sophie Lebel-Binay Ph.D. | Deputy CEO, Chief Scientific Officer & GM |
| Dr. Yannick Pletan M.D., M.Sc. | Deputy CEO, GM & Chief Medical Officer |
| Mr. Philippe Billiald Ph.D., Pharm.D. | Scientific Founder |
| Ms. Martine Jandrot-Perrus M.D., Ph.D. | Scientific Founder |
| Mr. Francois Guillet | Chief Financial Officer |
| Ms. Laurie Jullien Pharm.D. | Head of Regulatory Affairs |
| Ms. Victoria Rutman Pharm.D. | Head of Quality Assurance |
| Mr. Elie Toledano | Head of Scientific Affairs & Business Intelligence |
| Ms. Adeline Meilhoc | Head of Global Clinical Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 22.7989 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 31 |